Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADT withdrawal versus maintenance and intermittent versus continuous docetaxel in castration-resistant prostate cancer
2010-019004-24Phase 3Active
- Sponsor
- San Luigi Gonzaga Hospital
- Start
- May 2010
- Modality
- Small Molecules, Peptides, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of docetaxel, triptorelin and leuprolide in prostate cancer (PCa) (4 arms), sponsored by San Luigi Gonzaga Hospital. Primary endpoint: Overall survival. Started May 2010; status: active.
02
Drugs
docetaxeltriptorelinleuprolide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2010-019004-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019004-24.